These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11382139)

  • 1. [Tumor markers].
    Fiebiger W; Wiltschke C
    Acta Med Austriaca; 2001; 28(2):33-7. PubMed ID: 11382139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nipple fluid carcinoembryonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts.
    Zhao Y; Verselis SJ; Klar N; Sadowsky NL; Kaelin CM; Smith B; Foretova L; Li FP
    J Clin Oncol; 2001 Mar; 19(5):1462-7. PubMed ID: 11230492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
    Bretton PR; Evans WP; Borden JD; Castellanos RD
    Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the role of established tumour markers.
    Beastall GH; Cook B; Rustin GJ; Jennings J
    Ann Clin Biochem; 1991 Jan; 28 ( Pt 1)():5-18. PubMed ID: 2024935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites.
    Liu F; Kong X; Dou Q; Ye J; Xu D; Shang H; Xu K; Song Y
    Ann Hepatol; 2014; 13(3):357-63. PubMed ID: 24756011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
    Aus G
    Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of prostate-specific antigen density and transitional-zone prostate-specific antigen density in the diagnosis of prostate cancer].
    Martínez Jabaloyas JM; García Morata F; Villamón Fort R; Pastor Hernández F; Gil Salom M; García Sisamón F
    Actas Urol Esp; 2003 Jun; 27(6):442-9. PubMed ID: 12918151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
    Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
    Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Isoforms of free prostate-specific antigen].
    Haese A; Noldus J; Steuber T; Huland H; Lilja H
    Urologe A; 2004 Jun; 43(6):675-9. PubMed ID: 15221148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour markers in oncology: past, present and future.
    Magdelénat H
    J Immunol Methods; 1992 Jun; 150(1-2):133-43. PubMed ID: 1613250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New biomarkers for diagnosis and prognosis of localized prostate cancer.
    Chistiakov DA; Myasoedova VA; Grechko AV; Melnichenko AA; Orekhov AN
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):9-16. PubMed ID: 29360504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of tumour marker dual reporting during method transition: PSA high-dose hook effect detected.
    Kittanakom S; Donohue V; Beattie J; Clark L; Kavsak PA
    Clin Biochem; 2018 Nov; 61():45-46. PubMed ID: 30179593
    [No Abstract]   [Full Text] [Related]  

  • 15. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Beinert T; Fürst H; Fink U
    Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor markers in the diagnosis of malignant serous effusions.
    Cascinu S; Del Ferro E; Barbanti I; Ligi M; Fedeli A; Catalano G
    Am J Clin Oncol; 1997 Jun; 20(3):247-50. PubMed ID: 9167746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour markers--a diagnostic and therapeutic perspective.
    Aw SE; Sundram FX
    Ann Acad Med Singap; 1990 Mar; 19(2):244-50. PubMed ID: 2189345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
    Oesterling JE
    J Urol; 1991 May; 145(5):907-23. PubMed ID: 1707989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen.
    Brawer MK
    Semin Surg Oncol; 2000; 18(1):3-9. PubMed ID: 10617891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.